Mycotopia Therapies, INC

Aibotics Inc. has contracted GMF Ventures, LLC to develop iOS and Android applications for its Philbot massage robot for $165,000, with initial payment made in company stock.

Mycotopia Therapies has entered into an agreement with its largest shareholder, Ehave Inc., exchanging common stock for a new series of super voting preferred stock, granting Ehave significant control.

Mycotopia Therapies, Inc. has replaced its independent auditor, Pinnacle Accountancy Group of Utah, with Fruci & Associates II, PLLC, effective March 21, 2024.

Aibotics, Inc. reported a net loss of $1.61 million for the nine months ended September 30, 2025, with significant liquidity challenges and a working capital deficit.

Aibotics, Inc. reported a widening net loss and significant working capital deficit for Q2 2025, raising substantial doubt about its ability to continue as a going concern.

AIBiotics Therapies reports its Q1 2025 results, highlighting the emergence of revenue alongside continued net losses and concerns about its ability to operate as a going concern.

Mycotopia Therapies reports a net loss of $1.36 million for the nine months ended September 30, 2024, and expresses substantial doubt about its ability to continue as a going concern.

Mycotopia Therapies' Q2 2024 filing reveals a widening net loss and a working capital deficit, raising substantial doubt about the company's ability to continue as a going concern.

Mycotopia Therapies reports increased net loss and a growing working capital deficit in its Q1 2024 results, raising substantial doubt about its ability to continue as a going concern.

Aibotics, Inc. reports a net loss of $2.2 million for 2025 while pivoting its business focus toward AI-powered robotics and wellness products.

AIBotics, Inc.'s 2024 10-K filing reveals a widened net loss and a strategic shift towards artificial intelligence and robotics, particularly in the wellness and parenting sectors.

Mycotopia Therapies, Inc. reports a net loss for 2023 and a shift in business strategy towards AI-powered robotics following the acquisition of Philon Labs assets.

AIBOTICS, Inc. CEO Benjamin Kaplan acquired 75 million shares of common stock at $0.003 per share as payment for accrued salary, increasing his beneficial ownership to 95.25 million shares.

Mycotopia Therapies director, Mark Croskery, acquired 10 million shares of common stock in lieu of cash compensation for director's fees.

Mycotopia Therapies CEO, Benjamin Kaplan, acquired 20 million shares of common stock in lieu of cash compensation for director's fees.

Mycotopia Therapies Inc. will change its name to AiBiotics Inc. to reflect its shift towards using Artificial Intelligence in its business operations.